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Objectives. We sought to determine the frequency of sponlane- 
QIIS cerehrovasculaF events in adult patients with cyanotic con- 
genital heart disease and to evaluate any contributing factors. 
&&ground. Cerebrovasctdar events aFe a serious comphcation 
of cyanotic congenital heart disease in infants and children but 
are said to be uncommon iu adults. 
M&ods. Between 19R4 and 1995, 162 patients with cyanotic 
congenital heart disease (mean age 37 years, range 19 to 70) were 
retrospectively evaluated foF any well documented cerebrovascu- 
far events that occurred at ?I8 years of age. Events related to 
procedures, endocarditis or brain abscess were excluded. 
Rewlts. Tweuty-MO patients (13.6%) bad 29 cerebrovascular 
events (l/l@0 patient-years). There was no significant difference 
between those with and witbout a cerebrovascular event in terms 
of age, smoking history, degree of erythrocytosis, ejection fraction 
OF use of aspirin or warfarin (Coumadin). Patients who bad a 
Adult patients with cyanxic congenital heart disease are at an 
increased risk of hyperiiscosity secondary to erythrocytosis. 
One important issue that remains unsettled, however, relates 
to the risk of stroke ot cerebrovascular events in these cyanotic 
patients. Venous thrombosis and, less commonly, arterial 
thrombosis with secondary cerebrovascular accidents have 
been well documented in infants and children with cyanotic 
congenital heart disease (1,2). ‘Ibis is thought to be primarily 
related to an increased red blood cell mass, and occasionally, 
iron deficiency anemia is seen in these patients (1,3-e). Both 
of these factors have been implicated in increasing the whole 
blood viscosity, with frequent upper respiratory trset infec- 
tions, fever and dehydration playing a major contributing role 
In t& developmem of vessel thrombosis (4,7), Published 
reports, however, have not all agreed that adult patients with 
cyanotic congenital heart disease are also at risk of cerebro- 
vascular events or strckes (1). This prompted us to review ou; 
experience in the Adult Congenital Heart Disease Ciinic ro 
determine the frequmcy of cerehrovascular events in these 
patients and to mahate any contriinuting risk factors. 
___ 
cerebrovascular event had a significantly increased tendency to 
develop hypertension, atrial fibrillation, micreqtosis (mean CQF- 
puscnlar X&KSI~ ~$2) and history of phlebotomy (p C 0.05). Even 
when patients with hypertension or atrial fibrillation were ex- 
cluded, there was an increased risk of cerebrovascular events 
associated with microcytosis (p C 0.01). 
Conclusions. Adults with cyanotic congenital heart disease are 
at risk of having cerebrovascular events. This risk is increased io 
the presence of hypertension, atrial fibrillation, l&tory of phle- 
botomy and microcytosis, the latter condition having the strongest 
significance (p C 0.005). This finding leads us to endorse a more 
conservative approach toward phlebotomy and a more aggressive 
approach ioward treating microcytosis irt adults with cyanotic 
congenital heart disease. 
-.- 
Patient selection. We performed a retrospective review of 
the medical and surgieal records of all patients who attended 
the Adult Congenital Heart Disease Clinic since 1988. This 
included patients who had complex repair before their first 
visit, in which case clinical and neurologic events had to be well 
documented before their surgical intervention. Patients were 
included in the study if they had 1) a congenital anomaly 
consistent with cyanotic congenital heart disease surh as 
tetralogy of Pallot, a single ventricle or Eisenmenger’s syn- 
drome; 2) clinical cyanosis with a hemoglobin level 214.5 g/da; 
3) no history of carotid artery disease; and 4) no primary 
unracranial pathology such as a vascular malformation. 
One hundred &y-two patients 19 to 70 years old (mean 
37 5 11.6) met all four of the above criteria, Patients were 
divided into two groqss: Group I (n - 140) included those 
patients who had no history suggestive of a cerebrovascular 
event, and Group II fn = 22) included those who had a well 
dxumcr.ted cerebrovascnhr event manifcstcd by a transient 
ischcm2c attack, a reversible iwhemic neurologic deficit or a 
completed infarct. Transient iscshemir attack was defined as a 
tqnxxy neurofogic deficit corresponding Fo the anarornic 
distrih~tio~ of a carotid or vertebral artery that lasted ~23 h 
without any residual deficit. R~~ersihlc ischemir ne~rolo~~~ 
deficit was d&ted 3s a prolonged, fully reversible neurolitgic 
d&i: that could have lasted from 1 day to a &v a&s. The 
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completed infarct or Stroke was defined as a prolonged neu- 
rologic event that may or may not have been followed by only 
partial recovery wi:hin days to weeks, and preferably with a 
computed tomographic and/or magnetic resonance imaging 
(MM) scan documenting the brain infarct. 
Patients with cerebrovascular events were excluded from 
Jur analysis if the events occurred before 18 years of age (n = 
2). To determine the frequency of spontaneous cerebrovascu- 
lar events, patients were excluded if the events were related to 
procedures such as cardiaccatheterization or catheter ablation 
(n = l)? active infective endocarditis or brain absees~ jn = 2). 
Patients were also exc!uded if the cerebrovascular events were 
of unknown origin, such as from dizziness, generalized weak- 
ntiss or syncope of unclear etiology {n = 3). 
Clinica;al variables. The following clinical information and 
variables were obtained for all 162 patients-age at the time of 
the last clinic visit, gender, number of years of follow-up since 
age 18 years, history of systemic hypertension, tobacco abuse: 
or antecedent atria1 fibrillation. &formation related to a 
history of iron deficiency anemia, therapeutic phlebotomy or 
in take of aspirin or warfarin (Goumadin) wan also recorded. In 
addition, the degree of erythrocytosis (hemoglobin and hemat- 
ocrit) as well as mean corpuscular volume, oxygen saturation 
(when availabie) and ejection fraction of the systemic ventricle 
were reviewed. For patients with no history of cerebrovascular 
event (Group I), we chose thnsc ::dlues obtained during the last 
clinic visit as well as the patients’ most recent assessment of 
ejection fraction and oxygen saturation. For patients with a 
history of cerebrovascular events (Group II), we recorded 
hemoglobin, hematocrit, mean corpuscular volume and ejec- 
tion fraction at the time of the cerebrovascular event or shortly 
before it. When such data were unavailable, we reviewed the 
laboratory profile and selected those values that were obtained 
closest to the cerebrovas-cular event. 
Statistical analysis. Unpaired, two-sample t test analysis 
was performed for comparison of continuous variables such as 
ejection fraction between patients in Group I and Group II 
after appropriate testing for normality. Chisquare analysis was 
performed to compare discrete variables between the two 
groups. Data presented are mean value i SD. To assesS 
muitivariate relations Between patic.@. characteristics and a 
history of cerebrovascuIar events, multiple logistic regression 
analysis was performed with a history of cerebrmaseular event 
as the dependent variable. &.ly variables with an apparent 
univaridte association with cerebrovascufar events, as well as 
age and gender, were considered. 
One hundred sixty-two patients (86 men? ?6 women) aged 
14 to 70 years (mean 37) were included in our srudy (Iable 1). 
Fifty-one patients (31.5%) were Seen only once, when they met 
ihe inelusion criteria, including those who were rehrred for 
surgkai intervention and su~que,ntl~ bmame acyanouc. &- 
cauw af the retr~~c7~v~ nature of this rev+w, fiJlow-up ~3s 
availahie Ior up t(7 -51 yem @WI I9) from the enhcy), age: of IS 
Table 1. Clinical Yariables -1__1__-. - 
Group I Groep Ii 
(no CM?) (cm) Totilt P 
in = 140) in = 22) t,n = 162) Value ----. 
Age (ycm) 
Range 19-m 11-Y 14-X 
Mean t- SD 37212 4) t 12 37 ?. 12 0,226 
LMale~female 73167 1319 W76 0.51 
Diagmsis 
Complex $9 8 5: 
I%enmenge~e:‘s syndrome 45 6 51 
Pulmonary atresia i7 3 31 Q9-l 
Ebstein 22 3 lj 
Tetralo# of FaUot 6 2 8 
PYVSD 1 cl I 
~olInw-sp (years) 
Range l-52 3-39 1-s 
Mean 2 SD 18.“ i 11.7 22.2 rfr 12.1 19.4 i 11,s 0.23 
_- 
Unkss othensise indicated, data presented tire number of patients. CVE = 
cerebrovascular event; I’S = pulmonary s:‘3nosis; VSL) = ventricuiu sepmi 
defect. 
years. The remaining 111 patients (68.5%) were evaluasd 
more than once, and their follow-up evaluations ranged from 1 
to >30 years. Total follow-up was 3,135 patient-years (mean 
19.35 -t 11.8). 
Cerebrwassular events, One hundred forty patients (Group 
If had no history suggestive of cerebrovascular events occur- 
ring after 18 years of age, ?r:? 22 patients (13.6%, Group ]I) 
had a total of 29 CeFebrOvdsii&r events, including 19 transient 
ischemic attacks, 4 reversible ischemic neurologic deficits and 
6 s&&es. Six of these patients had more than one event, 
including one patient who had three events. The neurologic 
s,ymptoms associated with these cerebrovascular events in- 
cluded 18 events in which patients had signs and SynJptoms 
suggestive of hemiplegia, hemiparesis or sensory deficit, or a 
combination of these. Eight events were as&ated with visual 
disturbance Such as diplopia and homonymous hemianopsia.. 
Three events were manifested by amaurosis mga~ and another 
three events were associated with speech distarbanee. ‘l’bere 
was one cerebrovascular ev& maaifested by a lacunar infartzt 
documented by computed tomoFaphy of the brain. 
A normal computed tomographic andfor X312! scan of the 
brain was documented in 12 (52%) of 23 transient ischemic 
atzaeks cr reversible ischemic mmlogic dehdts. No mdio- 
graphic dccumentation was available for the remaining tran- 
sient ischemic attacks and reversib!e ischemic nemologic def- 
icits @ = 11). In contrast, all five patients who had a hisrorji of 
s:I’Gke f&d have c coaputed tomogzphic an$or MRI scan oi 
the brain during their events. Four patients had one brain. 
in&et each, and one pa&it had two infan.% Fi+e of these 
examinations showed hemispheric infarct, and one H~QS com- 
pletely normal. In additim. kur itf threw five patknb Woo irrtd 
a toeal of six iufarets had *a rtzidual neurotcgic d&it, and one 
drath.related &o ~ompli~ar~(~ns of the infarct occurred, 
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Table 2. HemQdynamic and Wematologic Variables 
Group I (no CVE) Groop II JCVF.) 
(n = 146) (” = Z:i) p wue 
Continues variable 
EF (%) 
Range 
Mean i- SD 
Hemoglobin 
Range 
Mean 2 SD 
Hematocrit 
4nnge 
Mean + SD 
MC?’ 
Range 
Mean 5 SD 
Discrete variable 
Hypertension 
Yes 
No 
Atrial fibrillaticm 
Yes 
NO 
Smoking 
Yes 
Nr 
Phlebotomy 
Yes 
NO 
IFOII deficiency anemiai 
microcytosis 
K‘es 
No 
Antiplateiet intake 
Yes 
No 
Warfarin intake 
Yes 
Na 
20-7d 
s3 r 9.8 
34-65 
ii2 i 8.9 
14.5-23.5 14.5-2X! 
17.7 i- 1.86 18.4 z 2.2 
41.7-70.1 41.3-63.1 
53.3 f 6.0 544 ” 6.7 
S7.4-104.5 
87.8 c 9.7 
4 
136 
13 
127 
0.7&J 
O.OSl 
C.li 
ON 
0.021 
0.015 
0.68 
O.Oib 
MM 
0.68 
0.29 
Unless otherwise indicated, data presented are number of patients. CVE = 
cerebrovnrcular event: EF = ejection fraction; MCV = mitan corpuscular 
voiumz. 
ital heart disease in these patients are shown in Table 1. 
Fifty-seven patients (35.2%) had complex congenital heart 
disease such as single ventricle or double-outlet right ventricle. 
Fifty-one patients (31.J%j had Eisenmcnger’s syndrome sec- 
ondary to an atriai septal defect, a ventdculnr septal defect, 
patent ductus arteriosus or truncus arterioaus. The dinicd 
variables of these tlvo groups of patients are aIso shown in 
‘Table j . There was no statisticaliy, significant difference be- 
tween Gmup I and Gmtip II patients in terms of age% gender. 
inem years of follow-up or ;tnatomic dia_mosis. 
saturation measurement was available in 75 patients in Group 
I (range 60% to 90% mean 80%) and 11 patients in Group II 
(range 66% to 88%, mean 80%). 
Systemic hypertension. Because this cohort is relatively 
ya;mg (maan age 37 yearsj), it is not surprising that the 
incidence of systemic hypertension is !OW (7 [4.3%] of 162). 
When comparing those patients with hypertension in Group I 
versus Group II, there appeared to be an increased risk of 
cerebrovascular events associated with hypertension (4 of 140 
vs. 3 of 22, p = Q.021) (Table 2). However, we recognize the 
small number of palients with a history of hypertension in our 
study group. When patients with such a histop (n = 7) were 
excluded from the analysis, the risk of cerebrovascular events 
continued to be high (14%), with 19 patients who had cere- 
brovascular events versus 136 patients who did root, 
Atkial fibrillation, A total of 19 patients had documented 
atriai fibrillation, parovsmal in 17 (I 1 in Group I, 6 in Group 
II) anl! chronic in 2 (Group I). There was a statistically 
significant difference between Group I and Group II in terms 
of history of atria1 fibriuation (p = 0.015) (Tat& 2). When the 
seven parier.ts with hypertension were excluded from the study, 
alriai fibrllaiioii remxin.ed an ir,)portant risk factor for cere- 
brovascular events (p = 0.033,13 of 136 in Group I vs. 5 of 19 
in Group II). However, when patients with atria1 fibriliation 
were excluded from the study, the incidence of cerebrovascular 
events remained high (12.6%), with 16 patients who had ~a 
event and 127 palients who did not. 
Tobacco use. Among the 162 patients, 143 (88.3%, 123 in 
Group I and 20 in Group II) never smoked tobacco, although 
19 (11.7%, 17 ir! Group 1 and 2 in Group II) did at some time 
during their life, including 12 patients who continued to do so 
at the time of their lagt clinic visit (Table 2). Chi-square 
analysis showed no statistical difference between Group I and 
Group II in terms of tobacco use, and therefore smoking was 
not associated with an increased risk of cerebrovascular events 
in this patient group. 
Hematologic profile, The mean hemoglobin level in our 
study group was 17.8 @dl, with a mean hematocrit of 43.3% 
and a mean corpuscular volume of 87.5. Unpaired t test 
analysis with a 95% confidence limit showed no statistical 
difference (p = Ml) between Group I and Group 11 in terms 
of hemoglobin and hematocrit (Table 2). Similarly, the mean 
red blood cell meal1 corpuscular volume did not differ signifi- 
cantly between Group I and Group II (Table 2j. 
Forty-one patients demonstrated iron deficienat anemia 
with mictuq:os,sis (mean corpuscular vdams < U).*TKs was 
either secondary to phlebutomy, gastrvini estinal bleeding or 
me!lorrBgia. ‘Eleven of these patients haa a cerebr0vasAsr 
event, demonstrating the very strorig a-w&on bergeen iron 
deficiency anemia \vith microq@& find F histq of cerebro- 
vasufar events (p - It.004~ (Table 2j. This statistically sign& 
icant assilcfation pa&ted even when patients wirh tryprten- 
sim and atria! ~br~~Iati~~ were excluded from the an@& fZ$ 
of 123 h-f Group 1 % 8 of 14 in Group 11). 
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ease who present with significant erythrocytosis (bttmogloh;n 
>20 g/d1 or hematocrit >6§%), unless they have symptoms of 
hyperviscosify. Nonetheless, 46 (28.4%) of the 162 patients had 
a history of phlebotomy; most of the procedures Bere pcr- 
formed befom their referral to our center. Eleven of these 
patients had cerebrovascular events, although 35 patients did 
not. A chi-square comparison between Group I and Group 11 
showed a significantly increased risk of cerebrovascular events 
after therapeutic phiebotomy (35 of 140 vs. 11 of 22, p = 
0.016). 
Antiplatelet amd warfarin intake. A total of 19 patients 
were taking either aspirin or dipyridamole, including 17 pa- 
tients in Group I and 2 patients in Group II. Another 18 
patients were taking warfarin, including 17 patients in Group I 
and only 1 patient in Group II. The indication for chronic 
anticoagulation with warfarin was atria1 fibrillation in five 
patients, pulmonary hypertension in five, a history of pulmo- 
nary embolism in two, a history of lower extremity edemai 
varicosities in two, mechanical valve prosthesis in one and 
marked depression of systemic ejection fraction in one. One 
patient had been placed on warfarin after a syncopal episode of 
unclear etiology? but the medication was discontinued on his 
first clinic visit. All of these 17 patients belonged to Group I. 
Only one patient was taking warfarin at the time of the 
cerebrovascular event. There was no statistically sigmficant 
decrease in the incidence of cerebrovascclar events in patients 
who were Faking either antiplateiet agents or war-farm. Subse- 
quent analysis of 21 patients with atria1 fibrillation or Butter 
(15 in Group I and 6 in Group II) also showed no statistically 
significant decrease in the incidence of cerebrovascular events 
associated with chronic anticoagulation (p > 0.5). 
In a multiple logistic regression analysis, haypertension (p = 
O.O40), atria1 fibrillation (p = 0.012) and microcyzosis (p = 
0.004) were signilicantly independently related to cerebrovas- 
cular eve&, When plttebotomy was added to this model, the 
significance was borderline (p = 0.115). 
Stroke is generally considered a disease of the elderly, with 
only 5% of cases occurring in patients ~45 years old (8). 
Howe\-er, the emotional, psychological and economic impact 
of crrebrovascular events is potentially devastating, *and so 
stroke prevention is verv imposmm The association between 
h<matologic disorders and stroke is well established. Patients 
with a primary red bload ~11 disorder such as polycythemi& 
r&t-a Y:FB are at an increased risk. of cerebrovascular everus 
the majority of which are cerebral infa.rcts related to vessel 
oc&ision rafher thus intracraia? hemorrhage (&9). In con- 
trast, patients wi?h qeno:Ee hcari disease do not have polyev- 
!klllid but have an mcre;l~ irr red cell miss. -&is secondary 
e@hrocytosis may increase blood viscosity and thereby reduce 
~mebral blood flr?w (4,7: IO). As a resni~, rhildren with t7;anotic 
congenital heart cl&a% 9re at increa& risk of cereb~ascu- 
8ar E3ent’i. The ma majority of fhe,se ttventri are cerebral 
venous rather than arteria1 thrombosis, and the reported 
incidence varies from 1.6% to 20% (3J1). 
Although the association between secondary erythrocytosis 
and the increased risk of cerebrovascular event is well docu- 
mented in infants and children with cyanotic congenital heart 
disease, recent reports have challenged this finding in the adult 
population. Perloff et al. (1) found no increased risk of stroke 
in 112 patients (mean age 36 5 11.7 years, range 19 to 74) with 
cyanotic congenital heart disease followed continuously from It 
to 12 years (total 748 patient-years). Our study is somewhat, 
similar in terms of patient selection. However, there are two 
major differences between the two studies. Firsif our study 
retrospectively evaluated any well documented cerebrovascu- 
Ix event since the age of 18 years, including those that 
occurred before the patients started attending the Adult 
Congenital Heart Disease Clinic, as well as those events rhat 
occurred before any surgical intervention corrected the cyano- 
sis. Thus, we report a longer duration of follow-up (3,135 vs. 
745 patient-years). Second, we did not exclude patients who 
had independent risk factors for stroke, such as tobacco use, 
hypertension and atria1 fibrillation, from our initial analysis. 
Nonetheless, when these patients were excluded, the inciderice 
of cerebrovascular events remained high (14.7%)~ with 16 
patients who had an event compared with 109 patients who did 
not. Our study is the first to show that the association be&veen 
cyanotic congenital heart disease and cerebrovascular events is 
real not only in children but also in ad& (incidence 13.6%> 
0.92 events per patient per 100 patient-years). More important, 
our study has shown that there are four independent risk 
factors associated with the development of cerebrovascu!ar 
events in adults-namely, systemic hypertensiont atriaf libril- 
lation, therapeutic phlebotomy and iron deficiency anemia/ 
microcytosis. 
Hypertension. Hypertension and atria1 fibrillation are well 
known independent risk factors for stroke. The number of 
patients with systemic hypertension is small (n = 7 [4.3%]jl hut 
there is reason to believe that patients with cyanotic congenital 
heart disease would benefit from adequate blood pressure 
control just like patients with other conditions, provided 
vasodilator drugs, which might increase right-to-ieft shunt and 
worsen cyanos%~ are avoided, 
A&la! ~b~latl~~. Numerous studies have demonstrated a 
clear benefit from the use of anticoaguiation. and to z lesser 
extt”nL from antiplatelet agents, in reducing the risk of cere- 
brovascular events in patients with atria1 fibrillation (Iz14). 
Sub~group analysis of all 19 patients with atria1 ~b~lation in 
our group (13 in Group I and 6 in Crutlp 11) showed no 
si~ifrcant d’itference from those who were tre:t?ed with Eong- 
term ant~~oagcilatjo~ in terms of risk of~er~~~r~v~~~r rvem 
and sClar results were found with antipfatelet agents. How- 
t-ler. the small number of patients in rhis subgroup precludes 
atry statist&l!!; sign&ant condusion fn view- of the potential 
hemorrhagic side effects o.f both antiplatelet agents and war- 
&in in these patients, who are aka known to be at increawd 
risk of bleeding (3,Tf; deci&ms regarding tbe!~ agents must be 
iod~vi(~~aI~ed~ 
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Phlebotomy. Therapeutic phlebotomy, which has long 
been used in patients with cyanotic congenital heart disease in 
the hope of reducing the risk of hyperviscosity and stroke, 
poses a potential hazard because of the possible risk of 
decompensated erythropoiesis and iron deficiency anemia 
(lJ5). In this study. 11 (50%) of the 22 parients with a history 
of cerebrovascular events had had a phlebotomy. Several 
investigators have demonstrated that iron deficiency anemia 
and micmqtosis pose an increased risk of cerebrovascular 
events in children with cyanotic congenital heart disease 
(2,3,5,X). This study is the first to report an increased risk in 
adults. Iron-deficient red blood cells are less deformable than 
normal red blood cells and do not pass through the microcir- 
culatlon as readily as iron-replete cells (2,7). This in itself will 
further increase whole blood viscosity and the risk of cerebro- 
vascular events in patients with cyanotic ccngeniial heart 
disease (2,4,7). 
Iron deficicirncy. Adult patients with cyanotic congenital 
heart disease are at risk of depleting tl&r iron stores and 
deveioping iron deficiency anemia either because of a pE&t- 
omy or sometimes because of heavy menses or gastrointestinal 
bleeding (3?7,16,17). Certainly the development of microcyto- 
sis poses the greatest risk for a cerebrovascular event. Our 
study demonstrates this clearly, as microcytosis was present in 
11 of 22 patients with a cerebrovascolar event. This stresses the 
importance of regular follow-up of the red blood cell indices in 
this patient group, especially if they havre a history of bleeding 
(gastrointestinal or gynecologic) or have had a recent phlebot- 
omy. 
Therapeutic implirations. This study is tile first to show a 
clear, statistically significant increase in the incidence of cere- 
brovascular events in adults with cyanotic congenital heart 
disease and iron deficietmy anemia and/or microcytosis. Even 
when patients with hypertension or atria1 fibrillation, or both: 
were excluded from the study, microcytosis was indeed the 
strongest risk factor associated with cerebrovascular events. 
This study therefore suggests a more aggressive approach to 
treating iron deficiency anemia or microcytosis, or a combina- 
tiom with iron replacement when the mean coqmxular WI- 
ume is G!. Restoring normocytosis should decrease the risk 
of cerebrovascular events. To avoid a rebound response by the 
bone marrow, howeve,, low dose ferrous sulfate (325 mgjday) 
is suggested with folG~up blood counts at 1 week, Iron 
replacement should be disco:iufxxd as soon ;1’; the hemoglobin 
starts to rise (15). This study also underscores the need to 
avoid a phlebotomy unless absolutely necessary (1) (hemoglo- 
bin >20 g/d1 or hematocrit XW%). Furthermore, when a 
phlebotomy is performed, it should be accompanied by iso- 
vohrmic fluid replacement, and the red blood cell indices 
should be closely monitored to prevent microbytosis and iron 
deficiency anemia (15). In contrast to the study by Berloff et al. 
(l), this study demonstrates that adult cyanotic patients who 
had neither phlebotomy nor microcytosis from any cause are 
still at significant risk of cerebrovascular events (7 [7.7%] of 91 
patients). 
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